Therefore, 6 months of chronic therapy with Sirolimus in Thalassemia patients did not perturb the percentages of different lymphoid and myeloid immune cells, with the exception of a slight and transient increase of CD8+ T cells after 3 months of therapy. The gene discussed is CD8A; the disease is thalassemia.